---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-005983"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T16:45:01.451616+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# AbCellera COO Lecault transitions to CTO; COO role dissolved

## Summary
- Effective Feb 18, 2025, Veronique Lecault moved from COO to CTO.
- Change agreed mutually, not due to any disagreement with company.
- COO position will not be filled and is dissolved.
- Lecault remains a director on the Board of Directors.

## SEC filing metadata
- accession: 0001628280-25-005983
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000162828025005983/0001628280-25-005983-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000162828025005983/abcl-20250218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-005983
- JSON: https://secwatch.observer/filing/0001628280-25-005983.json
- Plain text: https://secwatch.observer/filing/0001628280-25-005983.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.